Crossmark

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition

Crossref DOI link: https://doi.org/10.1186/s40425-019-0648-3

Published Online: 2019-07-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Naqash, Abdul Rafeh https://orcid.org/0000-0001-7622-720X
Appah, Ebenezer

Yang, Li V.

Muzaffar, Mahvish

Marie, Mona A.

Mccallen, Justin D.

Macherla, Shravanti

Liles, Darla

Walker, Paul R.
Funding

Funding for this research was provided by:

Lung Cancer Initiative of North Carolina

East Carolina University Coach Rock Fund
License Information

Text and Data Mining valid from 2019-07-05
More Information

Article History

Received: 28 March 2019

Accepted: 21 June 2019

First Online: 5 July 2019

Ethics approval and consent to participate

: Appropriate consent for conducting and reporting patient biomarker data presented in this manuscript was obtained from the ECU IRB (IRB 16–000719).

: Individual patient consent was not applicable as no information in this article including the images, can be categorized as identifiable.

: The authors declare that they have no competing interests.